Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Asensus Surgical Inc ASXC

Asensus Surgical, Inc. is a medical device company digitizing the interface between the surgeon and patient to reimagine surgery through Performance-Guided Surgery to enable surgeons to deliver outcomes to patients and establish a new standard of surgery. It operates in one business segment, which is the research, development and sale of medical device robotics to improve minimally invasive surgery. It is developing the LUNA Surgical System, a robotic and instrument system as a foundation of its Digital Surgery solution. These systems shall be powered by the Intelligent Surgical Unit to enhance surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, it intends to holistically address the clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. It is also working to incorporate all of this in the LUNA Surgical System.


NYSEAM:ASXC - Post by User

Post by tamarion Jan 16, 2021 6:55pm
334 Views
Post# 32314237

Clearance of Senhance Surgical System for General Surgery

Clearance of Senhance Surgical System for General Surgery

in the United States will open up Senhance to the highest volume and value procedures. 

Consider FDA clearance is typically expected within 6 months for filing, and TransEnterix announced filing on 4-Aug-2020.  If on schedule news may pop any day prior to 4-Feb-2021, or check for decision in the FDA database found here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm  (just plug TransEnterix into the Applicant Name field).

FDA approval will fit perfectly with what looks like a potential peak in "US Currently Hospitalized with COVID-19" per data compiled by The COVID Tracking Project:  https://covidtracking.com/data/charts/us-currently-hospitalized

These comments and snapshot on their Twitter site are encouraging. "On a national level, it appears COVID-19 hospitalizations are on the decline. Note: there are still some jurisdictions experiencing an overwhelming amount of hospitalizations." and "Some encouraging news: the 7-day averages for cases are declining in all 4 regions."
https://twitter.com/COVID19Tracking/status/1350243251987513344/photo/1
*see trend in the blue bars that indicate Currently Hospitalized Fell

The opportunities to apply Senhance will increase as hospitalizations & ICU occupancies fall. In 2010 the average ICU Occupancy was 67% according to the Society of Critical Care Medicine.  Various states are reacting to ICU  figures >70% as it represents a strain on hospitals.

Hospital staff are among the first to receive vaccinations; that's a great start.

The population most at risk (and contributing to increasing hospitalizations) is also among the first to be vaccinated.  Vaccinating those > age 65 it ought to reduce ICU occupancy quite a bit, clearing the path to address the huge surgical backlog and adopt the Senhance Surgical System.

Last link is this excellent vaccination tracker on Bloomberg.
https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

A possible inflection point or precipitous drop in COVID hospitalizations in the U.S., may occur once most of the >65 age bracket are vaccinated.  Gauge the figures presented on Bloomberg's Covid vaccine tracker against the U.S. population demographics to determine the theoretical inflection point (date). 

US demographics on Wiki show 65 and over at 13% of the population per the 2010 Census.
Current population estimate is 330,052,960 (2020) * 13% = 42,906,885 or ~43 million >65.
 

Under 18 years 24.0% (2010)[4]
18–44 years 36.5% (2010)[4]
45–64 years 26.4% (2010)[4]
65 and over 13.0% (2010)[4]

Using the Bloomberg data as of today -- Vaccinations in the U.S. began Dec. 14 with health-care workers, and so far 13 million shots have been given, according to a state-by-state tally by Bloomberg and data from the Centers for Disease Control and Prevention. In the last week, an average of 844,387 doses per day were administered.

43M - 13M = 30M remaining among the most at risk population.

Expanded rollout will increase daily vaccinations towards 1M/day, perhaps 1.5M per day.   That means all 65 million will be treated with at least their first dose by mid-February.  If a new agressive variant does not overwhelm the recovery, we ought to see a nice drop in hospitalizations by March accompanied by an uptick in general surgeries.





 

 

<< Previous
Bullboard Posts
Next >>